Article Text

Download PDFPDF

Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections
  1. James J DiNicolantonio1,
  2. Mark McCarty2 and
  3. Jorge Barroso-Aranda3
  1. 1Department of Preventive Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
  2. 2Catalytic Longevity, Encinitas, California, USA
  3. 3Clinica Libre de Adicciones, Tijuana, Mexico
  1. Correspondence to Dr James J DiNicolantonio; jjdinicol{at}


A recent retrospective study has provided evidence that COVID-19 infection may be notably less common in those using supplemental melatonin. It is suggested that this phenomenon may reflect the fact that, via induction of silent information regulator 1 (Sirt1), melatonin can upregulate K63 polyubiquitination of the mitochondrial antiviral-signalling protein, thereby boosting virally mediated induction of type 1 interferons. Moreover, Sirt1 may enhance the antiviral efficacy of type 1 interferons by preventing hyperacetylation of high mobility group box 1 (HMGB1), enabling its retention in the nucleus, where it promotes transcription of interferon-inducible genes. This nuclear retention of HMGB1 may also be a mediator of the anti-inflammatory effect of melatonin therapy in COVID-19—complementing melatonin’s suppression of nuclear factor kappa B activity and upregulation of nuclear factor erythroid 2-related factor 2. If these speculations are correct, a nutraceutical regimen including vitamin D, zinc and melatonin supplementation may have general utility for the prevention and treatment of RNA virus infections, such as COVID-19 and influenza.

  • coronary artery disease
  • acute coronary syndrome
  • coronary vessels

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Melatonin supplementation may reduce risk for COVID-19

A retrospective analysis of 791 intubated patients with COVID-19 has found that, after adjustment for pertinent demographics and comorbidities, those treated with melatonin had a markedly lower risk for mortality (HR: 0.131, 95% CI: 0.076 to 0.223)—suggestive of a profound anti-inflammatory benefit.1 Such an effect might be anticipated, in light of melatonin’s ability to upregulate expression of silent information regulator 1 (Sirt1)—a deacetylase that is known to suppress the activity of the proinflammatory nuclear factor kappa B (NF-kappaB) transcription factor—and also upregulate nuclear factor erythroid 2-related factor 2 (Nrf2), which promotes the transcription of a range of antioxidant proteins.2–4 Moreover, recent epidemiology suggests that melatonin usage may reduce the risk for contracting COVID-19. A recent retrospective study, examining data from 26 799 subjects in a COVID-19 registry and using propensity score matching to account for a range of covariates, found that current supplementation with melatonin was associated with a significant 28% reduction in risk for serologically detectible COVID-19 infection. Among Black Americans, this reduction in risk was a remarkable 52% (OR=0.48, 95% CI 0.31 to 0.75).5 The basis of this decrease in risk for COVID-19 is unclear, especially since Sirt1 activity, which melatonin promotes, is known to transcriptionally upregulate expression of ACE2—the cellular membrane receptor for COVID-19.6 7

Melatonin-induced Sirt1 may boost virally mediated mitochondrial antiviral-signalling (MAVS) activation

Here is a possible explanation. Melatonin, via its membrane receptors, induces nuclear translocation of the transcription factor retinoid-related orphan receptor alpha (RORα); RORα, in turn, promotes transcription of the gene encoding the clock transcription factor brain and muscle ARNT-like 1 (Bmal1). Bmal1 upregulates transcriptionally the expression of a number of proteins, including Sirt1 and Nrf2.2 8 9 The MAVS protein is a key mediator in the pathway of double-strand RNA sensing that leads to activation of interferon regulatory factor 3 (IRF3) and induction of type 1 interferons; its K63 polyubiquitination via TRIM31 triggered by upstream detectors of cytosolic double-stranded RNA, such as melanoma differentiation-associated protein 5 and RIG1, enable it to form multimers that promote activating phosphorylation of IRF3, which in turn induces the type 1 interferons.10–12 But the ubiquitinase ovarian tumour ubiquitinase 3 (OTUD3) opposes this activation by deubiquitinating MAVS.13 The activity of OTUD3 in this regard hinges on acetylation of its Lys129; Sirt1 can remove this acetyl group, turn off OTUD3 activity and thereby upregulate viral activation of MAVS and type 1 interferon induction.13 For reasons still unclear, RNA viral infection causes Sirt1 to associate with OTUD3, such that the latter is deacetylated and thereby inactivated, enabling the K63 polyubiquitination of MAVS and subsequent multimer formation.13 figure 1 attempts to clarify these relationships.

Figure 1

How melatonin up-regulates induction of type 1 interferons and interferon-stimulated genes (ISG) by inhibiting OTUD3 and promoting nuclear retention of HMGB1, while combating inflammation via inhibition of NF-kB activity, up-regulation Nrf2, and prevention of extracellular release of HMGB1.

The net effect of Sirt1 on interferon-mediated antiviral immunity is however complicated by the fact that Sirt1 inhibits NF-kappaB’s transcriptional activity; NF-kappaB also functions downstream from MAVS to promote the induction of type 1 interferons.11 14 15 The cellular response to RNA viruses typically activates IRF3, NF-kappaB, ATF2 and c-Jun, all of which can bind to the promoter of the interferon-β gene and promote its transcription. However, there is evidence that activation of IRF3, in the absence of NF-kappaB, ATF2 or c-Jun activation, can drive transcription of the interferon-β gene.16 Notably, in HEK293T cells infected with Sendai virus, transfection with Sirt1 more than doubles the mRNA expression of interferon-β1, despite the potential inhibitory impact of Sirt1 on NF-kappaB activity.13 Analogously, resveratrol, a Sirt1 activator, doubles interferon-β mRNA induction in Huh7 cells infected with dengue virus.17

In light of the fact that melatonin enhances Sirt1 expression via activation of Bmal1, it is pertinent that knockout of Bmal1 in mice impairs their ability to control pulmonary infections with the Sendai and influenza RNA viruses.18

Sirt1 may also amplify response to interferons by preventing nuclear export of high mobility group box 1 (HMGB1)

Sirt1 activity may also boost the antiviral response triggered by type 1 interferons. In response to inflammatory signals or certain viral infections, the damage-associated molecular pattern protein HMGB1 is hyperacetylated, causing its export from the nucleus and enabling its release from the cell.19 The p300/CBP-associated factor acetylase complex can mediate this acetylation, as has been demonstrated in dengue virus-infected cells.20 By reversing such acetylation, Sirt1 tends to keep this protein confined to the nucleus, where it has been shown to boost the transcription of type 1 interferon-stimulated antiviral genes.17 21 22 In this regard, HMGB1 has been shown to associate with the promoter region of the interferon-stimulated gene MxA.17 Indeed, the acetylation of HMGB1, triggered by viral infection, may represent a viral stratagem for suppressing expression of these antiviral genes. Hence, measures which enhance Sirt1 activity may both potentiate RNA virus-mediated induction of interferon-β and also render cells more sensitive to the antiviral activity of this cytokine. Figure 1 summarises these pathways.

Release of HMGB1 from virally infected cells stimulates the inflammatory activation of nearby myeloid cells, as it can act as an agonist for toll-like receptor 2 (TLR2), toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) receptors.23 It has been credibly argued that HMGB1 release may play a key role in triggering or exacerbating pulmonary inflammation in COVID-19 infection.24–26 Sirt1-mediated nuclear retention of HMGB1 may represent one important mechanism whereby melatonin administration aids resolution of COVID-19 infection. Additionally, as noted, Sirt1 opposes synthesis of proinflammatory cytokines by its inhibitory impact on NF-kappaB activity—which is downstream from the receptors activated by HMGB1.

Clinically, Sirt1 activity can also be boosted by agents such as metformin that activate AMP-activated kinase; this reflects the ability of adenosine AMP-activated protein kinase (AMPK) to induce nicotinamide ribosyltransferase, the rate-limiting enzyme for biosynthesis of Sirt1’s obligate substrate NAD+.27 28 However, AMPK also suppresses mechanistic target of rapamycin complex 1 (mTORC1) activity, which is required for type 1 interferon synthesis, and this effect appears to predominate.29 With respect to the phytochemical resveratrol, which is reported to activate Sirt1 in rodent studies, its pharmacokinetics when administered orally in humans are too poor for it to be clinically useful in this regard.30 31 Nonetheless, it is intriguing that this Sirt1 activator has shown antiviral effects against a range of viruses in rodent and cell culture studies.32

These considerations suggest that melatonin supplementation may help to prevent and control RNA virus infections via upregulation of virally mediated type 1 interferon induction; melatonin may also enhance the antiviral activity of these interferons by maintaining the nuclear localisation of HMGB1. These hypotheses should be readily testable in animal models of viral infection, and, if confirmed, could point toward another valuable clinical application for this safe and affordable neurohormone nutraceutical.

Toward nutraceutical prevention of viral infections

More generally, it might be feasible to define a simple nutraceutical regimen that could reduce the risk for COVID-19 and a range of other viral infections. There is growing evidence, both case–control and ecologic, that replete vitamin D status not only markedly improves the clinical course of COVID-19, but also is associated with decreased risk for clinically detectible infection.33 34 Arguably, this might reflect upregulated lung production of defensins such as cathelicidin, the production of which is driven by calcitriol, which can be synthesised in lung cells that express 25-hydroxyvitamin D 1-α hydroxylase in response to inflammation.35 36 Cathelicidin is not only bactericidal, but also disrupts enveloped viruses such as SARS-CoV-2 and influenzas.37–39 Epidemiologic studies have correlated higher vitamin D status with lower risk for influenza and upper respiratory infections.40 41 COVID-19 epidemiology also suggests that higher zinc status is associated with both a better clinical course in this disorder and lower risk for infection.42 43 Especially in the elderly, who are more prone to poor zinc status, zinc supplementation has been found to boost acquired, antigen-specific immunity, while also exerting an anti-inflammatory action; such supplementation of the elderly was associated with a marked decrease in total infections in a 12-month randomised controlled trial.44 45 More speculatively, supplementation with glucosamine or with high-absorption sources of quercetin may have potential for boosting the type-1 interferon response and reducing viral infection risk.46–49 Hence, it is not unreasonable to suggest that a supplementation programme incorporating vitamin D, zinc, melatonin and possibly additional nutraceuticals could reduce risk for and aid control of COVID-19 and a range of other viral infections.

In regard to melatonin dosing, it should be acknowledged that, when used in the context of virally induced cytokine storm, multiple daily doses may be appropriate to optimise its anti-inflammatory efficacy. Indeed, a recent case series of 10 patients with COVID-19 pneumonia noted that melatonin supplementation (36–72 mg per day given in four divided doses) was associated with a reduction in hospital stay, mortality and mechanical ventilation.50 The large retrospective study of melatonin use in intubated patients with COVID-19 cited above does not clarify the dosing schedules employed.1 Whereas, when used in a preventive mode, bedtime dosing is appropriate so as not to disrupt circadian rhythm.



  • Contributors All authors contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MM is an owner of a nutraceutical company. JJD is a director of Scientific Affairs for Advanced Ingredients for Dietary Products.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.